Loading...
•
Dec 31, 2023
Vistagen Q3 2024 Earnings Report
Reported financial results for the third quarter of fiscal year 2024 and provided a corporate update.
Key Takeaways
Vistagen reported a net loss of $6.3 million for the third quarter of fiscal year 2024, with cash and cash equivalents of approximately $126.6 million as of December 31, 2023. The company is progressing with clinical trials for fasedienol, itruvone, and PH80.
PALISADE-3 trial initiation for fasedienol is anticipated in 1H 2024.
PALISADE-4 trial initiation for fasedienol is anticipated in 2H 2024.
Phase 2B development is underway for itruvone for major depressive disorder.
Phase 2B development is underway for hormone-free PH80 for women's health indications.
Vistagen
Vistagen
Vistagen Revenue by Segment
Revenue by Segment
Sublicense and other Revenue
CapyFin.com Forward Guidance
Vistagen is focused on advancing its clinical programs, including fasedienol, itruvone and PH80.
Positive Outlook
- On track to initiate PALISADE-3 Phase 3 trial in SAD during the first half of this year.
- Making significant progress toward Phase 2B development of itruvone for major depressive disorder.
- Continue to make significant progress toward Phase 2B development of hormone-free PH80 for women's health indications.
- PALISADE-4 trial is anticipated to be initiated in the second half of 2024.
- Either PALISADE-3 or PALISADE-4, if successful, together with the positive results from PALISADE-2, may establish substantial evidence of the effectiveness of fasedienol
Challenges Ahead
- Risks and uncertainties in the process of development and commercialization
- No guarantee that any of the Company’s drug candidates will successfully complete ongoing or future clinical trials
- No guarantee to receive regulatory approval or be commercially successful
- The Company may not be able to successfully replicate the result of past studies of its product candidates
- Other technical and unexpected hurdles in the development, manufacture and commercialization of the Company’s product candidates.